Open Access Repository

Targeting epigentic modifiers in cancer


Downloads per month over past year

Holloway, AF ORCID: 0000-0003-2213-1717 and Oakford, PC 2007 , 'Targeting epigentic modifiers in cancer' , Current Medicinal Chemistry, vol. 14, no. 24 , pp. 2540-2547 .

[img] PDF
4431.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.


The chromatin structure of a gene plays an important role in regulating its expression. This structure is established through the action of various protein complexes that remodel nucleosomes, catalyse post-translational modifications, deposit histone variants and methylate DNA. Together these complexes establish epigenetic marks that influence expression of the gene. Some of these epigenetic marks are transient while others, such as those involved in silencing genes are more stable and can require several cell divisions to be fully implemented or reversed. Deregulated gene expression programs are a feature of cancer biology and it is now apparent that epigenetic changes, as well as genetic changes, are important in establishing these aberrant expression patterns. However, unlike genetic alterations, epigenetic changes are reversible. The complexes that catalyse these modifications therefore represent valuable targets for therapeutic intervention. Here we will review the most recent literature describing the protein complexes that catalyse epigenetic modifications and the inhibitors of these complexes that are being pursued as cancer drugs. In addition we will highlight those epigenetic modifiers that provide promise as therapeutic targets but for which inhibitors are not currently available.

Item Type: Article
Authors/Creators:Holloway, AF and Oakford, PC
Journal or Publication Title: Current Medicinal Chemistry
Publisher: Bentham Science Publishers Ltd
ISSN: 0929-8673
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page